Compare Novavax Inc (NVAX) vs Paycom Software Inc (PAYC) Price & Performance

Novavax (NVAX) trades at $11.22, down 0.88% on the day, with a bullish technical signal from moving averages and a neutral RSI. The company reported strong revenue of $1.12 billion in 2025 and a net income of $440.30 million, but faces negative cash flow and a projected net loss for 2026. Recent news highlights its strategic pivot to a partnership-driven model using its Matrix-M adjuvant technology, with regulatory approvals for its updated COVID-19 vaccine in key markets.

The outlook for NVAX is mixed, with analyst consensus strongly favoring a buy rating (73.92%) but significant financial risks including negative equity, persistent cash burn, and volatile earnings. Investment opportunity lies in the successful execution of its licensing strategy and expansion into oncology, though execution risks and competitive pressures remain key concerns for shareholders.

Paycom Software (PAYC) trades at $230.80, up 3.23% with strong technical momentum and bullish moving average signals. The company demonstrates robust fundamentals with 10% revenue growth in Q2 2026, 83.67% gross margins, and consistent earnings beats. Recent institutional buying and positive analyst coverage support the stock's upward trajectory, though valuation multiples remain elevated compared to industry peers.

Outlook remains positive with raised 2026 guidance targeting 7-8% revenue growth and 46% EBITDA margins. Key risks include competitive pressures in payroll software and market volatility. The consensus price target of $207.75 suggests potential downside from current levels despite strong operational performance.